Literature DB >> 27161045

Adherence to topical therapies in actinic keratosis: A literature review.

Peter Foley1, Eggert Stockfleth2, Ketty Peris3, Nicole Basset-Seguin4, Rino Cerio5, José Antonio Sanches6, Carlos Guillen7, Emily Farrington8, Mark Lebwohl9.   

Abstract

BACKGROUND: Actinic keratosis (AK) is a common skin condition, for which topical therapies are frequently prescribed. This review summarises current understanding of patient adherence and persistence to topical AK treatment by identifying literature relating to measures of adherence and persistence and influencing factors.
METHODS: A multi-database literature search was conducted (2004-2015) using key search terms. Supplementary searches of pivotal clinical trials and reference lists of eligible papers were also conducted.
RESULTS: Non-adherence and non-persistence rates varied between real-world studies (10-63% and 23-31%, respectively), with combined non-adherence and non-persistence reported as high as 88%. Methods to calculate adherence and persistence differed between studies. Adherence and persistence were generally higher in clinical trials than clinical practice. Key contributing factors to non-adherence and non-persistence to AK treatment were identified as: treatment duration, severity and persistence of local skin responses and patient confusion over treatment regimens.
CONCLUSION: The review highlighted a significant evidence gap regarding adherence and persistence to topical AK therapies. Combined, non-adherence and non-persistence may be as high as 88% in clinical practice, highlighting the importance of incorporating contributing factors to patient non-adherence into treatment decisions.

Entities:  

Keywords:  actinic keratosis; adherence; field therapy; persistence; squamous cell carcinoma in situ; topical treatment

Mesh:

Year:  2016        PMID: 27161045     DOI: 10.1080/09546634.2016.1178372

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  4 in total

Review 1.  Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update.

Authors:  Spencer M Vale; Dane Hill; Steven R Feldman
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

2.  Approaches to Field Therapy for Actinic Keratoses: Relating Clinical Trial Results to Real-world Practice-A Commentary.

Authors:  David M Pariser
Journal:  J Clin Aesthet Dermatol       Date:  2022-04

3.  Three-Day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: Cosmetic Outcomes and Patient Satisfaction from a Phase II Trial.

Authors:  Brian Berman; Stephen Tyring; Walter K Nahm; Marie Louise Østerdal; Astrid H Petersen; Daniel M Siegel
Journal:  J Clin Aesthet Dermatol       Date:  2017-11-01

4.  Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome.

Authors:  Khaled Ezzedine; Caroline Painchault; Melanie Brignone
Journal:  J Mark Access Health Policy       Date:  2020-10-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.